Oxford MND Care & Research Center

University of Oxford

The Oxford Motor Neurone Disease Care & Research Center provides diagnosis and multidisciplinary care to patients with ALS and related disorders from a large geographical area of Southern England.

Oxford_Logo
University of Oxford

The Oxford clinic’s core team comprises three neurology consultants, a nurse consultant, a specialist nurse and occupational therapist. We work closely with respiratory and gastroenterology colleagues. There are ~250 individuals living with MND and related disorders in active follow-up, with 130 new patient referrals annually. In addition to participating in clinical trials, we run a number of research programs. Professor Talbot leads on the cellular biology including the development of rodent models and stem cell-derived motor neuron culture systems. Professor Turner leads a large biomarker program combining multimodal neuroimaging with biofluid sampling. Dr Thompson is focused on biofluid protein characterization, including pre-symptomatic cohorts through our Families for the Treatment of Hereditary MND (FaTHoM) initiative. We organise MND training courses for allied healthcare professionals.

Contact
Location
John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, United Kingdom

Our specialists

Martin Turner

Professor of Clinical Neurology and Neuroscience

Martin Turner qualified in Medicine from University of Cambridge and St. George’s […]

Martin Turner
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more